Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VIP236 |
Synonyms | |
Therapy Description |
VIP236 is a small molecule-drug conjugate comprising an alpha5beta3 integrin-targeted molecule linked to a modified camptothecin payload, which potentially induces cytotoxic effects against tumor cells and inhibition of tumor growth (PMID: 35053556). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VIP236 | VIP-236|VIP 236 | VIP236 is a small molecule-drug conjugate comprising an alpha5beta3 integrin-targeted molecule linked to a modified camptothecin payload, which potentially induces cytotoxic effects against tumor cells and inhibition of tumor growth (PMID: 35053556). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05712889 | Phase I | VIP236 | Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer | Recruiting | USA | AUS | 0 |